(MedPage Today) — The FDA granted accelerated approval to atacicept (Trutakna) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
Data from ORIGIN 3 supported approval of the once-weekly self-administered…
Source link : https://www.medpagetoday.com/nephrology/generalnephrology/122087
Author :
Publish date : 2026-07-07 20:51:00
Copyright for syndicated content belongs to the linked Source.
